The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (“NUVB” or “the Company”) (NYSE: NUVB) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nuvation reported its Q4 and full year 2025 financial results on March 2, 2026. As part of an update on the commercial launch of its IBTROZI oncology therapy, the Company revealed that a significant portion of its early patient starts were in later-line treatment settings, and that 75% of its treatment discontinuations were part of these later-line patient populations. According to the Company, these discontinuations contributed to the gap between the number of patients starting IBTROZI and its net product revenue growth. Based on this news, shares of Nuvation fell by 25.3% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

View source version on businesswire.com: https://www.businesswire.com/news/home/20260321759252/en/